Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Technology evaluation: DISC.

E S Robertson1

  • 1Department of Microbiology and Immunology, University of Michigan Medical School, Ann Arbor, MI 48019-0620, USA. esrobert@umich.edu

Current Opinion in Molecular Therapeutics
|March 16, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Human papillomavirus prevalence among unvaccinated young female college students in Botswana: A cross-sectional study.

South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde·2022
Same author

EBV PCR in the diagnosis and monitoring of posttransplant lymphoproliferative disorder: results of a two-arm prospective trial.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2008
Same author

The Kaposi's sarcoma-associated herpesvirus latency-associated nuclear antigen binds to specific sequences at the left end of the viral genome through its carboxy-terminus.

Virology·2002
Same author

The latency-associated nuclear antigen encoded by Kaposi's sarcoma-associated herpesvirus activates two major essential Epstein-Barr virus latent promoters.

Journal of virology·2001
Same author

An Epstein-Barr virus isolated from a lymphoblastoid cell line has a 16-kilobase-pair deletion which includes gp350 and the Epstein-Barr virus nuclear antigen 3A.

Journal of virology·2001
Same author

Latency-associated nuclear antigen encoded by Kaposi's sarcoma-associated herpesvirus interacts with Tat and activates the long terminal repeat of human immunodeficiency virus type 1 in human cells.

Journal of virology·2001
Same journal

Gene therapy: Have the risks associated with viral vectors been solved?

Current opinion in molecular therapeutics·2011
Same journal

Teduglutide, a glucagon-like peptide-2 analog for the treatment of gastrointestinal diseases, including short bowel syndrome.

Current opinion in molecular therapeutics·2010
Same journal

Dulaglutide, a long-acting GLP-1 analog fused with an Fc antibody fragment for the potential treatment of type 2 diabetes.

Current opinion in molecular therapeutics·2010
Same journal

Corticorelin, a synthetic human corticotropin-releasing factor analog, for the treatment of peritumoral brain edema.

Current opinion in molecular therapeutics·2010
Same journal

Mogamulizumab, a humanized mAb against C-C chemokine receptor 4 for the potential treatment of T-cell lymphomas and asthma.

Current opinion in molecular therapeutics·2010
Same journal

Gevokizumab, an anti-IL-1β mAb for the potential treatment of type 1 and 2 diabetes, rheumatoid arthritis and cardiovascular disease.

Current opinion in molecular therapeutics·2010
See all related articles

Cantab

Area of Science:

  • Gene therapy
  • Oncolytic virus
  • Herpes simplex virus (HSV) vector technology

Background:

  • Cantab is developing its proprietary DISC technology for gene therapy applications.
  • The DISC technology uses a modified herpes virus as a vector for gene delivery.
  • DISC technology is being explored for cancer (DISC-Onc) and neurological/blood disorders (DISC-GT).

Purpose of the Study:

  • To evaluate the potential of DISC technology as a gene therapy vector.
  • To assess DISC-Onc for cancer treatment and DISC-GT for neurological and blood disorders.
  • To investigate the efficacy and safety of DISC-Onc in preclinical cancer models.

Main Methods:

  • Utilizing a replication-deficient herpes simplex virus vector.
  • Delivering immunogenic genes (e.g., GM-CSF, cytokines) into cancer cells.

Related Experiment Videos

  • Evaluating gene transfection rates and anti-tumor activity in animal models and human cancer cell lines.

    • Main Results:

    • DISC-Onc demonstrated significant therapeutic effects in animal tumor models.
    • Effective gene delivery to human colorectal, gastric, and ovarian cancer tumors was achieved.
    • DISC-Onc with GM-CSF showed anti-tumor activity in renal cancer and leukemia mouse models.
    • DISC-GT enables long-term gene expression in nerve cells.

    Conclusions:

    • DISC technology shows promise as a versatile gene therapy vector for various diseases.
    • DISC-Onc is a viable candidate for cancer gene therapy, with favorable transfection rates and anti-tumor effects.
    • DISC-GT holds potential for treating neurological disorders through sustained gene expression in nerve cells.